Analysts Have Conflicting Sentiments on These Healthcare Companies: Inmune Bio (INMB) and Joint (JYNT)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Inmune Bio (INMB) and Joint (JYNT).
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Inmune Bio (INMB)
In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Inmune Bio, with a price target of $8.00. The company’s shares closed last Friday at $1.43.
According to TipRanks.com, McCarthy is ranked 0 out of 5 stars with an average return of
Inmune Bio has an analyst consensus of Strong Buy, with a price target consensus of $8.00.
See today’s best-performing stocks on TipRanks >>
Joint (JYNT)
In a report released yesterday, Anthony Vendetti from Maxim Group maintained a Hold rating on Joint. The company’s shares closed last Friday at $8.69.
According to TipRanks.com, Vendetti has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Currently, the analyst consensus on Joint is a Hold with an average price target of $10.00, implying a 10.1% upside from current levels. In a report issued on April 27, Craig-Hallum also maintained a Hold rating on the stock.
Read More on INMB:
